Mesa Laboratories Inc: (NASD: MLAB)
$53.10
-0.14 (-0.26%)
Volume 6,570
Jun 19 04:00 PM ET
Zacks Rank: NA 
| |
Full Company Report
MESA LABORATORIES, INC. designs, develops, acquires, manufactures and markets instruments and systems utilized in connection with industrial applications and hemodialysis therapy.
General Information
MESA LABS INC
12100 W 6TH AVE
LAKEWOOD, CO 80228
Phone: 3039878000
Fax: 303-987-8989
Web: http://www.mesalabs.com
Email: InvestorRelations@mesalabs.com
| Industry | MED INSTRUMENTS |
| Sector | Medical |
| Fiscal Year End | March |
| Last Reported Quarter | 03/31/2013 |
| Next EPS Date | 08/08/2013 |
Price and Volume Information
| Zacks Rank |  |
| Yesterday's Close | 53.24 |
| 52 Week High | 57.00 |
| 52 Week Low | 40.00 |
| Beta | 0.38 |
| 20 Day Moving Average | 24,692.45 |
| Target Price Consensus | 59.00 |
% Price Change
| 4 Week | 0.00 |
| 12 Week | -1.74 |
| YTD | 6.13 |
Share Information
| Shares Outstanding (millions) | 3.40 |
| Market Capitalization (millions) | 180.80 |
| Short Ratio | 5.30 |
| Last Split Date | NA |
% Price Change Relative to S&P 500
| 4 Week | 1.05 |
| 12 Week | -6.97 |
| YTD | -7.41 |
Dividend Information
| Dividend Yield | 1.05% |
| Annual Dividend | $0.56 |
| Payout Ratio | 0.20 |
| Change in Payout Ratio | -0.05 |
| Last Dividend Payout / Amount | 05/22/2013 / $0.14 |
EPS Information
| Current Quarter EPS Consensus Estimate | NA |
| Current Year EPS Consensus Estimate | NA |
| Estimated Long-Term EPS Growth Rate | NA |
| Next EPS Report Date | 08/08/2013 |
Consensus Recommendations
| Current (1=Strong Buy, 5=Strong Sell) | 1.00 |
| 30 Days Ago | 1.00 |
| 60 Days Ago | 1.00 |
| 90 Days Ago | 1.00 |
Fundamental Ratios
P/E
| Current FY Estimate | NA |
| Trailing 12 Months | 18.68 |
| PEG Ratio | NA |
Price Ratios
| Price/Book | 3.41 |
| Price/Cash Flow | 13.26 |
| Price / Sales | 3.89 |
Current Ratio
| 03-31-13 | 4.17 |
| 12-31-12 | 4.30 |
| 09-30-12 | 4.96 |
Net Margin
| 03-31-13 | 18.20 |
| 12-31-12 | 18.32 |
| 09-30-12 | 20.30 |
Inventory Turnover
| 03-31-13 | 3.19 |
| 12-31-12 | 3.34 |
| 09-30-12 | 3.29 |
EPS Growth
| vs. Previous Year | 9.21% |
| vs. Previous Quarter | 48.21% |
ROE
| 03-31-13 | 20.57 |
| 12-31-12 | 20.85 |
| 09-30-12 | 22.37 |
Quick Ratio
| 03-31-13 | 2.98 |
| 12-31-12 | 2.93 |
| 09-30-12 | 3.29 |
Pre-Tax Margin
| 03-31-13 | 27.93 |
| 12-31-12 | 28.04 |
| 09-30-12 | 31.13 |
Debt-to-Equity
| 03-31-13 | 0.08 |
| 12-31-12 | 0.10 |
| 09-30-12 | 0.17 |
Sales Growth
| vs. Previous Year | 21.69% |
| vs. Previous Quarter | 12.74% |
ROA
| 03-31-13 | 15.56 |
| 12-31-12 | 16.00 |
| 09-30-12 | 17.35 |
Operating Margin
| 03-31-13 | 21.84 |
| 12-31-12 | 22.24 |
| 09-30-12 | 23.93 |
Book Value
| 03-31-13 | 15.61 |
| 12-31-12 | 14.92 |
| 09-30-12 | 14.46 |
Debt to Capital
| 03-31-13 | 7.05 |
| 12-31-12 | 9.08 |
| 09-30-12 | 14.19 |
